CHC – The Cancer & Hematology Centers

In the News

As the largest physician-owned oncology and hematology practice in Michigan, we are often in the news. See what we've been up to.
The Faces of Breast Cancer Care

Cancer & Hematology Centers of Western Michigan’s Breast Team, is featured in a Grand Rapids Magazine’s segment on Faces of West Michigan. Click Here to read the aricle.   Founded in 1979, CHCWM has grown to become the largest physician-owned Read more »


Cancer & Hematology Centers of Western Michigan Joins OneOncology

A new partnership with Nashville, Tenn.-based OneOncology — a consortium for independent community oncology practices — offers Cancer & Hematology Centers capabilities in analytics and clinical technology as well as national partnerships to share best clinical practices and expand services in cancer Read More »


Yuanbin Chen, MD, JTO Clinical & Research Reports

Cancer & Hematology Centers of Western Michigan (CHC)’s Yuanbin Chen, MD, is published from CASPIAN on JTO as first author from CHCWM. DR. Chen reports this is the first time that immunotherapy plus chemotherapy works in small cell lung cancer Read more »


Yuanbin Chen, MD, European Lung Cancer Congress

Cancer & Hematology Centers of Western Michigan (CHC)’s Yuanbin Chen, MD, is featured in a study with the European Lung Cancer Congress, Characteristics of Long-Term Survivors in the CASPIAN study. “There were >3 times as many LTS in the D+EP Read more »


APP Nurse Practitioner Tami Groothuis
CHCWM’s Tami Groothuis, NP, partners with Livestrong program

Cancer & Hematology Centers of Western Michigan (CHCWM)’s Tami Groothuis, NP, recently beat cancer and is paying it forward by becoming a Livestrong coach, offering fitness classes for cancer survivors at the YMCA of Greater Grand Rapids. She spoke recently Read more »


START Midwest physician and clinical trial featured on ‘OncLive’

START Midwest’s Nehal Lakhani, MD, PhD, was recently featured on OncLive after his poster examining SL-172154 (SIRPα-Fc-CD40L) was presented at the 2021 Society for Immunotherapy of Cancer (SITC)’s Annual Meeting. The investigative agent was found to be “well tolerated with Read more »


Page 4 of 11
Page: